Citius Oncology supports TenX Keane Acquisition with $67K to Extend Deal Deadline
Acquiring Company
Citius Oncology
Acquired Company
TenX Keane Acquisition
CranfordBiotechnologyHealth CareMedicalTherapeuticsPharmaceuticalBiopharmaDescription
Citius Oncology, a subsidiary of Citius Pharma, has provided $66,667 to TenX Keane Acquisition, extending their deal deadline to June 18. The agreement also includes terms for the target to receive 67.55 million shares and retain 90% ownership, with Citius Pharma contributing $10 million in cash and assuming 12.75 million existing options. At closing, remaining cash in the TenX trust account and Citius Pharma's cash will support ongoing operations and planned commercialization efforts of Citius Oncology.
Quick answer
Citius Oncology is acquiring TenX Keane Acquisition for $0.1 million, announced May 22, 2024. Citius Oncology is based in Cranford, New Jersey, United States.
- How much did Citius Oncology pay for TenX Keane Acquisition?
- The reported deal value is $0.1 million.
- What does Citius Oncology do?
- Citius Oncology, Inc. is a Delaware-based clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of cancer.
- Where are Citius Oncology and TenX Keane Acquisition based?
- Citius Oncology is based in Cranford, New Jersey, United States.
- Who are the decision-makers at Citius Oncology?
- Fundz holds 2 contacts at Citius Oncology. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Medical and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- AbbVie finalizes acquisition of Landos Biopharma, Inc. to advance treatment for ulcerative colitis and Crohn's disease (May 23, 2024)
- Cycle Pharmaceuticals proposes to acquire Vanda Pharmaceuticals for $8.00 per share (June 6, 2024)
- Harmony Biosciences acquires Epygenix Therapeutics, Inc. to expand rare epilepsy franchise (April 30, 2024)
- Nuvation Bio Inc. completes acquisition of AnHeart Therapeutics Ltd. to enhance its oncology pipeline (April 10, 2024)
- Future Pak proposes acquisition of Vanda Pharmaceuticals for $7.25 to $7.75 per share in cash (April 17, 2024)
- Sanofi completes acquisition of Inhibrx, Inc. to enhance rare disease pipeline (May 30, 2024)
Who to call at Citius Oncology, and when
When Citius Oncology changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Citius Oncology raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Citius Oncology, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Citius Oncology. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Citius Oncology makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired TenX Keane Acquisition?
TenX Keane Acquisition was acquired by Citius Oncology, based in Cranford. The deal was reported on May 22, 2024. Citius Oncology, Inc. is a Delaware-based clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of cancer. Citius Oncology is publicly traded (CTOR) and operates in Biotechnology.
When did Citius Oncology acquire TenX Keane Acquisition?
Citius Oncology's acquisition of TenX Keane Acquisition was reported on May 22, 2024. Citius Oncology, a subsidiary of Citius Pharma, has provided $66,667 to TenX Keane Acquisition, extending their deal deadline to June 18. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does TenX Keane Acquisition do?
TenX Keane is a company that merged with Citius Pharmaceuticals, Inc. to form publicly listed Citius Oncology, Inc. on Nasdaq under ticker CTOR. It is privately held.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.